Elevar Therapeutics has relocated its headquarters from Salt Lake City to Fort Lee. The fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients said the move comes as it prepares to file a New Drug Application with the U.S. Food and Drug Administration for rivoceranib.
Elevar and its parent company, HLB, are developing rivoceranib in combination with Hengrui Pharma’s PD-1, camrelizumab, as a treatment option for hepatocellular carcinoma, the most common type of liver cancer. Elevar intends to submit the NDA filing for the combination therapy during the first half of 2023.
“Elevar is excited to debut our U.S. headquarters in New Jersey as we move closer to an NDA for rivoceranib in combination with camrelizumab as a treatment option for patients with unresectable HCC,” Saeho Chong, CEO of Elevar, stated. “Now is the right time to make this move, establishing Elevar’s presence amid some of the biggest pharmaceutical companies in the world, and some of the best talent.”
The new headquarters is located in 1 Bridge Plaza (North Central Road, Suite 850), directly across the Hudson River from New York City. Elevar will maintain an office in Utah and also has offices in California, Ireland and South Korea.
“Though Elevar is fully committed to remaining a remote work company, locating our headquarters in New Jersey will help us further build our staff and give team members an option to work from our offices should they wish to,” Chong said. “We are thrilled to call Fort Lee home.”
